A-share market movement | The Hantavirus outbreak draws attention! The virus prevention and treatment sector collectively surged, with Wantai Biotech up 9% and BGI Genomics rising over 5%.

Gelonghui, May 11 | Virus prevention and control concept stocks collectively rose in the A-share market. Among them, Walvax Biotech surged 19%, Capricorn Bio-Tech increased by over 15%, Daan Gene hit a 10% price limit, Wantai BioPharm gained 9%, Kangtai Biological Products rose over 8%, Zhifei Biological Products climbed 7%, and Frontier Biopharma-U, Probiotics Pharmaceuticals, CanSino Biologics, Wondfo Biotech, and Kanghua Biological Products increased by over 6%. Additionally, Jindike Biologics, BGI Group, Sichuan Maik Biotechnology, and TopRim Pharmaceuticals saw gains exceeding 5%. In terms of news, the cruise ship 'Hondeus' recently reported an outbreak of Hantavirus. Furthermore, a fatal case of Hantavirus was reported in Taipei City, Taiwan, related to infections carried by rats, drawing significant public attention.

Gelonghui FinanceMay 11 13:35

Express News | The concept of virus prevention and control surged again, with DAAN Gene hitting the daily limit in a straight line.

BreakingsMay 11 13:14

A-share market movement | Increased attention on the hantavirus outbreak has driven up the virus prevention and treatment sector, with BGI Group and Wantai BioPharm rising over 6%.

Gelonghui, May 8 | Virus prevention and control stocks in the A-share market collectively surged. Among them, Zhongsheng Pharmaceuticals and Daan Gene achieved a 10CM limit-up, Tuoxin Pharmaceuticals rose over 7%, BGI Genomics, Dian Diagnostics, Capable Biomedical, and Wantai Biological increased by more than 6%, Warner Pharmaceutical rose over 5%, Auto Bio rose over 4%, and Gongdong Medical and Sailun Biological climbed over 3%. In terms of news, following an outbreak of Hantavirus on a cruise ship, the Dutch Ministry of Health announced on May 7 that a Dutch woman suspected of being infected with Hantavirus had been hospitalized for treatment. The World Health Organization held a press conference on May 7 regarding the much-discussed Hantavirus outbreak on the 'Hondecoeter' cruise ship.

Gelonghui FinanceMay 8 10:09

BGI Group's valuation is expected to rise: Intelligent transformation redefines the core, globalization expands boundaries.

While the capital market is still abuzz with discussions on how large-scale AI models could revolutionize cognition, an even more profound transformation is quietly brewing in the biopharmaceutical field. The In Vitro Diagnostics (IVD) industry, once a high-flying sector, is now widely experiencing structural growing pains marked by volume and price pressures alongside slowing growth. However, the latest earnings report from BGI Genomics (300676.SZ) has cast a ray of hope over this gloomy market: In Q1 2026, the company achieved operating revenue of 809 million yuan, representing a year-on-year increase of 20.35% against the prevailing trend; its net profit attributable to shareholders also saw a significant reduction in losses, improving by 81.93% year-on-year. Against the backdrop of an overall sluggish industry

Gelonghui FinanceMay 6 14:55

BGI Genomics (300676): Improved efficiency drives significant reduction in net loss.

The company's revenue/parent company net profit/non-recurring net profit for 2025 amounted to RMB 3.705 billion/-RMB 617 million/-RMB 636 million, respectively. While revenue declined by 4.2% year-over-year, the parent company’s net loss narrowed by 31.7% and the non-recurring net loss decreased year-over-year.

Huatai SecuritiesApr 28 00:00

Breakthrough 'black tech' in cancer treatment accelerates deployment, ushering in a 'cell-level' era for precision radiotherapy.

Following the recent public endorsement by BGI CEO Yin Ye and the therapy's prominent appearances at major medical device exhibitions, this treatment, hailed as a 'breakthrough in cancer treatment,' is becoming a focal point in the market.

lanjinger.comApr 27 20:19